^
    Back
    Association details:
    Biomarker:RET G810C + CCDC6-RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    ESMO.org
    Title:

    Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

    Published date:
    04/11/2020
    Excerpt:
    RETG810C mutant was detected in cfDNAs of a CCDC6-RET-fusion NSCLC patient who developed acquired resistance to selpercatinib.
    DOI:
    10.1016/j.annonc.2020.10.599